The first step in the attack of human immunodeficiency virus (HIV-1) on human T lymphocytes is binding of the viral coat protein, gp120, to the CD4 antigen on the surface of the cells. The present study examines 1251_gp120 binding to CEM and U937 cells. The results of this study show that this process is more complex than previously thought, consisting of multiple binding components, some of which may reflect processes occurring after the actual binding. Despite its complexity, measurement of the inhibition of 1251_gp120 binding by monoclonal antibodies to the CD4 antigen or to gp120 generally parallels direct measurement of the inhibition of HIV-1 binding to cells expressing the CD4 antigen (CD4 positive). Furthermore, aurintricarboxylic acid and pentosan polysulphate, inhibitors of the association of HIV-1 with cells, also inhibit 1251_gp120 binding. This is the first case in which a small molecule has been shown to inhibit gp120 binding using a classical radioligand binding assay. Two other inhibitors of HIV-1 association with cells, dextran sulphate and chondroitin sulphate, were less effective as 125I-gp120 binding inhibitors, suggesting that prevention HIV-1/cell association can be produced by mechanisms other than direct inhibition of gp120/CD4 binding.
Introduction
Acquired immune deficiency syndrome (AIDS) is believed to result from the destruction by the human immunodeficiencyvirus (HIV-1) of human T lymphocytes that express the CD4 antigen (Fauci, 1988) . The initial event in the infection of these lymphocytes by HIV-1 is binding of the virus to the cells via an interaction between the viral envelope protein, gp120, and the host cell CD4 cellsurface antigen (Sattentau and Weiss, 1988) . Several agents that prevent the binding of HIV-1 to cells expressing the CD4 antigen are effective in combating HIV-1 infection of cells in vitro. Among these are monoclonal antibodies to selected epitopes of either the CD4 antigen or gp120 (McDougal et sl., 1986; Sattentau et aI., 1986) ; soluble CD4 receptor, which competes with cell-bound CD4 antigen for viral binding (Deen et sl., 1988; ; polysulphate polymers, such as dextran sulphate and pentosan polysulphate (Saba et al., 1988a; Mitsuya et al., 1988) ;and aurintricarboxylic acid (Schols et al., 1989) . These findings suggest that drug-induced blockade of HIV-1 binding to cells is a viable strategy for the treatment and prevention of AIDS, and that agents that inhibit gp120 binding to the CD4 antigen should specifically block HIVc1 binding to cells.
The binding of gp120 to the CD4 antigen is generally treated as analogous to the competitive binding of a ligand to its receptor (Lasky et et., 1987; Linsley et al., 1988; Pert et al., 1986; Schnittman et aI., 1988; Smith et aI., 1987) . This seems appropriate since the CD4 antigen may indeed act as receptor (Veillette et al., 1989) , and gp120 may mimic its endogenous ligand (Fields et al., 1988; Kornfeld et al., 1988) . The results of these studies indicate that gp120 binds to a single class of sites on CD4-expressing cells with nanomolar affinity and that its binding is inhibited by unlabelled gp120, or selected antibodies to CD4, in an apparently competitive fashion (Lasky et al., 1987; Linsley et al., 1988; Pert et al., 1986; Schnittman et al., 1988; Smith et aI., 1987) . The present study had two goals. The first was to confirm and supplement the published information concerning gp120 binding. The second goal was to determine using the radioligand binding assay, whether several compounds that block the association of HIV-1 with cells might do so specifically by inhibiting gp120 binding. In the Course of the study, however, unexpected complexities in the binding of gp120 were discovered, and attempts were made to explain these complexities.
Results
Aliquots of 1251-radiolabelled gp120 derived from HIVinfected cells and recombinant vaccinia virus were analysed by SDS-PAGE (Fig. 1 ). The gp120 ligand derived from the recombinant vaccinia virus was highly purified, with few additional radiolabelled bands present ( Fig. 1 , Specific 1251-gp120 binding to CEM cells reached a plateau after 2 h at 37°C ( Fig. 2a) . A particularly noteworthy. finding was that a portion of the specific binding was not readily reversible ( Fig. 2b ). Even 4h after removal of the unbound ligand and, in some cases, addition of G17-2, only about 50% of the specifically bound 1251-gp120 had dissociated. Irreversible binding suggests that an event such as receptor sequestration or internalization is taking place after the binding of the ligand (Boeynaems and Dumont, 1975) . The K_ I based the reversible portion of the binding (seven experiments) at 1.27 ± 0.15 x 10-2 min"". This value, in combination with the association data, yielded a K I of 1.73 ± 0.28 x 10 7 min -1 M-1 and a K d of 0.74 ± 0.19nM (four experiments).
Saturation experiments using CEM cells produced binding isotherms that were surprisingly complex. These curves had at least three components ( Fig. 3a ). Scatchard plots, however, were not concave, as would be expected in the case of multiple non-interacting binding sites (Boeynaems and Dumont, 1975) , but instead contained three convexities ( Fig. 3b ). Convex Scatchard plots are lane 2). Western blot analysis (not shown) confirmed this, and demonstrated that gp160 and gp41 were absent, as expected, since only the HIV-1 gp120 coding sequence was inserted into the vaccinia virus. The gp120 from HIV-infected cells (Fig. 1 , lane 1) was less pure than the vaccinia gp120 or HIV Virus-derived gp120 (data not shown). Some radiolabelled contaminants were visible at 70000 and 50000MW, and traces of gp160 and gp41 were detectable by Western blot. SDS-PAGE analysis of the ligand at the end of the binding protocol demonstrated that the radiolabelled gp120 was not degraded during the binding assay.
Radioiodinated C 25 1_) gp120 bound to CD4-expressing CEM cells, as reported in the literature (Lasky et el., 1987; Linsley et aI., 1988; Pert et al., 1986; Schnittman et al., 1988; . The binding appeared to occur at the CD4a epitope, since it was inhibited by monoclonal antibodies to this epitope (Sattentau et aI., 1986) , but not by a monoclonal antibody to the HLA class I cell-surface antigen, W6/32 (Table 1) . Furthermore, the binding was not inhibited by the monoclonal antibody, OKT4, which recognizes the CD4b epitope and does not block HIV-1 binding (Sattentau et a/., 1986) . Eighty percent of the binding was inhibited by prior exposure of the cells to 5 f,Lg ml" of the monoclonal antibody to the CD4a epitope, G17-2. This portion of the binding was considered specific. fitting techniques. As an approximation for comparison with published results, the initial component or the saturation curve, representing ligand concentrations below 0.5nM, was fitted. This analysis gave an apparent K d of 1.99 ± 0.26nM and a B max of 2.09 ± 0,44fmol million cells':" (n = 12). In order to explore the possibility that the complex nature of the gp120 binding isotherms was due to a post-binding process, two variations were made to the saturation experiments. First, the CD4 antigens were cross-linked with OKT4 and goat anti-mouse antibody. If a post-binding process, such as receptor sequestration, were occurring, it should be promoted by the clustering of the CD4 antigens (Gex-Fabry and Delisi, 1984; Stach and Perez-Polo, 1987) .Second, the incubation was performed at 4°C. Lowering the incubation temperature should inhibit post-binding events, which are dependent on active processes and affected by changes in membrane fluidity (Woodruff and Neet, 1986 ). Both of these variations had the effect of altering the second binding component ( Fig.  3 ). Cross-linking of the receptors increased the size of the second component, while decreasing the size of the first. Incubation at low temperature, on the other hand, decreased overall binding, but virtually eliminated the second binding component.
1251-gp120 binding to CEM cells was inhibited by prior incubation with unlabelled gp120 (Fig. 4) . The IC 50 value for unlabelled gp120 was 12 nM. Recombinant gp160 also inhibited 1251-gp120 binding but was fourfold less potent than gp120 (Table 1) . The gp120 fragment, gp120 254-274, which does not appear to be involved in the binding of HIV-1 to cells (Ho et al., 1988) , did not inhibit gp120 binding. Several peptides not related to gp120 were also inactive. Monoclonal antibodies to gp120 had varying effects. The antibody, 110-4, potently inhibited binding while 110-1 was inactive, as previously reported (Linsley et al., 1988) . The antibody, anti-HIV-1-envelope, was inactive.
Several compounds reported to inhibit HIV-1 binding to cells (Baba et al., 1988a; Mitsuya et al., 1988; Robinson et al., 1987; Zimmer et al., 1986) were also examined as 1251_gp120 binding inhibitors (Table 1) . Aurintricarboxylic acid was effective in inhibiting the binding (Fig. 5 ). An analogue of this compound that does not block the association of HIV-1 with cells, aurin (Schols et al., 1989) , did not inhibit gp120 binding. Pentosan polysulphate was also active in inhibiting gp120 binding ( Fig.5 ). On the other hand, consistent inhibition of gp120 binding could not be obtained with dextran sulphate (MW 5000, 8000 or 500000), although some inhibiton was occasionally seen. Surprisingly, the related polysulphated polymer, chondroitin sulphate, which like pentosan polysulphate blocks the association of HIV-1 with cells, was inactive. Diphenylhydantoin was also inactive. Lentil-lectin increased both a 20 40 60 80 100 120 140 160 180 200 Time (min) seen in cases of positively co-operative binding (Boeynaems and Dumont, 1975) . In such cases the initial binding of ligand to a receptor enhances subsequent binding. The shapes of both the saturation isotherms and their Scatchard representations were highly reproducible and were seen in all of the saturation experiments performed (n = 12). Furthermore, a similar binding isotherm and Scatchard plot was obtained using a CD4-positive cell line ofdifferent haematopoietic origin, U937 cells (data not shown). Because of the small size of the highest affinity component it was represented by a low amount of radioactivity actually bound. In order to more convincingly demonstrate the presence of this component, the incubation volume was increased 10-fold. Increasing the assayvolume without altering the concentration of cells or ligand does not change the characteristics of the binding, but increases the absolute number of D.P.M. bound. The specific binding in this experiment ranged from 330 to 1580 D.P.M. The high affinity binding component was clearly demonstrated in this experiment, and its Scatchard plot was obviously convex (Fig. 3 , bottom). True K d and B max values for gp120 binding to CEM cells could not be obtained from these saturation curves by standard curve- 5} 40 0 total and non-specific (i.e. not G17-2-inhibitable) binding of 1251-gp120, possibly by causing aggregation of the ligand (Robinson et al., 1987) , but did not decrease specific binding. As a test for the specificity of binding inhibition by anti-HIV-1 compounds, compounds that inhibit HIV-1 infection by means unrelated to a blockade of HIV-1 binding (OeClerq, 1989; Faber et al., 1987) , such as the nucleoside analogue, 3'-azido-3'-deoxythymidine (AZ1), 2',3'-didehydro-3'-deoxythymidine (041) and dideoxyinosine (001) the phosphonate PMEA, and fusidic acid were also examined. As expected, all were inactive as binding inhibitors.
Discussion
The binding of gp120 to cells proves to be an unexpectedly complex process. Three unusual aspects of this binding, it may be related to such processes. Although the function of a postbinding event, if it occurs, is unclear, it could contribute to the processes taking place following viral binding that lead to fusion of the virus with the cell. The complexity of gp120 binding was not due to such factors as ligand impurity, degradation of the ligand during the incubation, or peculiarities in the CEM cells used. Thus, although the gp120 purified from virus or Hlv-intected cells contained small amounts of gp41 and/or gp160, such contaminants were not present in the gp120 derived from cells infected with recombinant vaccinia virus, which gave identical results. Furthermore, the vaccinia-derived gp120 did not require purification on antibody affinity columns and, hence, was not exposed to denaturing conditions. In addition, the ligand was not degraded by the assay conditions, as shown by SOS-PAGE analysis. Finally, binding isotherms of the same shape were obtained with both CEM and U937 cell lines. Other conceivable explanations for the multiple binding components are that several distinct types of binding sites, each displaying positive co-operativity, actually are present, or that the ligand aggregates during the incubation period. These hypotheses have yet to be tested.
It is notable that the gp120 binding complexities observed in the present experiments were not reported in the studies of others (Lasky et el., 1987; Linsley et al., 1988; Pert et al., 1986; Schnittman et al., 1988; Smith et al., 1987) .This may be because other investigators used less thorough assays which, therefore, might not highlight these complexities. For example, some i.nvestigators constructed Scatchard plots solely from data produced by inhibition experiments, and most used fewer data points. In fact, the K d obtained in the present study by an analysis of only the initial component of the Scatchard plots does agree with literature values. Also, the kinetic experiments necessary to show irreversible binding have not previously been done.
The K d value of the reversible 1251-gp120 binding, calculated from the kinetic data (0.7nM), differs from that estimated from the initial component of the saturation isotherms (1.99nM), and both of these differ from the IC 50 value for gp120 (12nM) obtained at low ligand concentrations. This disparity supports the other data suggesting that gp120/CD4 binding is not a simple competitive process occurring at a single site. An accurate model for the binding, accounting for the multiple components, must be developed before the true binding parameters can be calculated.
Although 1251-gp120 binding to the CD4 antigen is a complex process, measurement of its inhibition by antibodies to gp120 or the CD4 antigen produces results comparable to the direct measurement of inhibition of HIV-1 binding tocells. Thus, both processes are inhibited by antibodies to the CD4 antigen such as G17-2 and binding are demonstrated by the present results. First, there are multiple components to the binding. The saturation experiments suggest three components. Second, a portion of the binding is irreversible. In dissociation experiments, approximately one-half of the 1251-gp120 remainedbound for at least 4 h after removal of the ligand. Third, the binding appears to occur in a positively cooperative fashion, as demonstrated by the convexities in theScatchard representation of the data. One possible explanation of the complicated nature of 1251-g120 binding to CEM and other cells is the presence of events occurring after the binding. In some systems, following the binding of the ligand, the receptor-ligand complex becomes sequestered or internalized (Gex-Fabry and Delisi, 1984; Stach and Perez-Polo, 1987; Woodruff and Neet, 1986) . These processes give rise to multiple binding components and to irreversible binding (Chandler and Herschman, 1983 ). In addition, some ligands that undergo sequestrations or internationalization also bind in a co-operative fashion (Woodruff and Neet, 1986) . In an attempt to evaluate this possibility, a saturation experiment was performed at 4°C. Low temperatures generally attenuate post-binding events by decreasing membrane fluidity and inhibiting active processes. Although overall binding is reduced at 4°C, the second binding component seems particularly attenuated. In another experiment, the receptors were caused to cluster by first binding OKT4 to them, and then cross-linking the OKT4 with a goat anti-mouse monoclonal antibody. This process should facilitate receptor sequestration or internalization, which may require receptor clustering (Gex-Fabry and Delisi, 1984; Stach and Perez-Polo, 1987) . This treatment broadens the second binding component. Given that the second binding component is affected in the expected manner by manipulations designed to alter events occurring after the OKT4A and the antibdoy to gp120, 110-4. Conversely, neither is blocked by the monoclonal antibody, OKT4. More interestingly, two synthetic compounds, aurintricarboxylic and pentosan polysulphate, are able to inhibit gp120 binding. Aurintricarboxylic has similar potencies in inhibiting gp120 binding and blocking viral association with cells, but pentosan polysulphate is much less potent as a gp120 binding inhibitor than a viral binding inhibitor (Saba et el., 1988a; Schols, et al., 1989) .Aurintricarboxylic has also been reported to block the binding of OKT4A to the CD4 antigen, whereas pentosan polysulphate lacks this activity (Schols et al., 1989) . Interestingly, aurintricarboxylic acid was a more efficacious inhibitor of gp120 binding than pentosan polysulphate, inhibiting 84% of the binding (double-reciprocal plot) compared to 64% for pentosan polysulphate. This suggests that pentosan polysulphate is either not a competitive inhibitor or not inhibitory towards all binding components. Other compounds that inhibit the binding of HIV-1 to cells are, however, inactive as gp120 binding inhibitors. Thus diphenylhydantoin (Zimmer et 81., 1986) and lentil-lectin (Robinson et al., 1987) do not inhibit gp120 binding. Furthermore, chondroitin sulphate fails to inhibit binding, while dextran sulphate does so only inconsistently. This implies that these compounds inhibit HIV-1 association with cells in a less selective manner, as has been suggested by others (Zimmer et al., 1986) . HIV-1 binding to cells may, therefore, be disrupted by processes other than the inhibition of gp120/CD4 binding. The greater ability of pentosan polysulphate to inhibit gp120 binding may explain why it is more potent in blocking in vitro HIV-1 infection and has a higher ratio of anti-HIV-1 to anticoagulant activity than dextran sulphate or chondroitin sulphate (Saba et al., 1988b , DeClerq, 1989 .
In conclusion, the present study demonstrates that the binding of gp120 to the CD4 antigen is a complex process and that much additional study will be necessary before it is completely understood. It also illustrates, however, that the radioligand binding assay, When used with discretion, is a powerful tool in the search for agents that, by blocking the association of HIV-1 with cells through inhibition of gp120 binding, may possess a novel type of anti-HIV-1 activity. Finally, the present study shows for the first time that a small molecule, aurintricarboxyiic acid, is capable of inhibiting 1251-gp120 binding to the CD4 antigen in a classical receptor binding assay.
Materials and Experimental procedures

Materials
The monoclonal CD4 antibodies OKT4 and OKT4a were purchased from Ortho Diagnostics (Raritan, NJ).G17-2 was provided by J. Ledbetter, Oncogen Corp., Seattle, WA (Ledbetter et a/., 1987) . Anti-T4 was purchased from Olympus Immunochemicals (Lake Success, NY). Using the system for classification of CD4 antibodies described by Sattentau et al. (1986) , G17-2 and anti-T4 reactivity places them in the same CD4 cluster as OKT4a. Antibody W6/32 (a gift of P. Parham) is reactive with cell-surface human HLA class 1 antigens (Parnham at a/., 1979). Antibodies 110-1 and 110-4 were produced by Genetic Systems Corp., Seattle, WA (Schrier and Goldstein, 1987) . 110-1 reacts with a peptide comprising amino acids 489--511 of gp120 and does not neutralize HIV-1. Antibody 110-4 interacts with a peptide comprising amino acids 303-323 of gp120 and neutralizes the LAV (HTLV Ill) strain (Kinney -Thomas et a/., 1988) . Anti-HIV-env was purchased from Olympus Immunochemicals (Ho et a/., 1988) .
gp120254-2 7 4 was purchased from Bachem (Torrance, CAl. Pentosan polysulphate and dextran sulphate (MW 5000, 8000 and 500000) were purchased from Sigma (St Louis, MO). The remainder of the monoclonal antibodies, compounds, and peptides were purchased from Sigma or Bioproducts for Science (Indianapolis, IN), or prepared in-house.
Culturing of CEM and U937 cells
CEM and U937 cells were cultured in RPMI-1640 (Gibco, Grand Island, NY) and 10% foetal bovine serum (J.R. Scientific, Woodland, CAl. The cells were grown to a density of 1.5 million cells mr" in 890cm 2 roller bottles (Falcon, Becton-Dickinson, Lincoln Park, NJ), and were supplemented with fresh medium 24 h priorto their use in the assay.
Preparation of gp120, gp160, and 1251_gp120
So/ubilization of g/ycoproteins. (i) Virus. HIV (LAV s ru ) was recovered from the supernatant of infected CEM cells using low and high speed centrifugation procedures. The virus was solubilized for 1 h at 4°C in buffer containing 1% NP40. The solubilized virus was stored frozen and subjected to infectivity testing prior to further use. (ii) HIV-1-infected cells. CEM cells at late stage of infection with HIV(LAV s ru ) (-46% viable) were harvested and resuspended at 10 Bml-1 in a buffer containing 2% Triton X-100 and the protease inhibitor PMSF. Following solubilization for 2 h at room temperature, the cell supernatant was Clarified by centrifugation at 15 OOOgfor 45 min. The cell lysate was stored frozen and subjected to infectivity testing prior to further use.
Isolation of gp120. The detergent solubilized viral or celllysates were diluted to 0.25% NP40 and the glycoprotein fraction collected on a lentil-lectin Sepharose 4B column. The column was eluted with a buffer containing 0.5 M methyl mannoside and 0.25% Triton X-100. To remove gp41 and any contaminating gp160, the lentiHectin column eluate was run over an anti-gp41 affinity column (antibody 41-1; Schrier and Goldstein, 1987) . Gp120 was isolated from the flow through fractions by passage over an anti-gp120 affinity column (antibody 110-1; Schrierand Goldstein, 1987) . The column was then washed extensively in buffer without detergent until spectrophotometric determinations of the wash confirmed detergent removal. The gp120 was eluted using a 1:100 dilution of triethylamine in saline, pH 11.5. Eluting fractions were immediately neutralized using excess Tris buffer at pH 7.4. Fractions containing gp120 were pooled and dialysed against three changes of phosphate-buffered saline (PBS). Protein concentration was estimated by absorption at 205 nm using the procedure of Scopes (1986) .
Preparation of ligand from recombinant vaccinia virus-infected cells. (i) gp160.
A recombinant vaccinia construct containing the sequence for HIV-1 gp160 (Venv-5) was used (Hu et al., 1986) . Briefly, BSC40 cells were infected overnight and then detergent disrupted according to the procedures described above. Gp160 from lentil-lectin column eluates was isolated free of gp41 and gp120 by reversal of the sequence of affinity chromatography described above. (ii) gp120. A recombinant vaccinia virus construct containing the sequence for HIV-1 (V-gp120) was used to infect BSC40 cells. With this constructthe majority of the gp120 is secreted and can be recovered from the media by binding to a lentil-lectin column. No detergents were used in the purification process.
Radioiodination ofgp 120 and gp 160. Lyophilized preparations of glycoproteins (~3.5 J-Lg) were labelled with~300 J-LCi di-iodinated Bolton-Hunter reagent (NEN, Wilmington, DE; 4400Ci mmol "}, A molar ratio of 3.4: 1 (Bolton-Hunter reagent to glycoprotein) was used. Labelling was conducted for 2 h at room temperature in PBS at pH 8.0. Unincorporated Bolton-Hunter reagent was removed by separation on a PD10 column (Pharmacia, Uppsala, Sweden) equilibrated with PBS, 1 mg rnr' gelatin, and 0.02% sodium azide. Incubation of the column-purified radioiodinated gp120 (1 25 1 -gp120) with CEM cells under conditions of binding site excess demonstrated that at least 36% of the label was present in a form that was able to bind. The labelled ligand was stored at 4°C and used within 1 week. 125/_gp 120 binding assay CEM or U937 cells, cultured as described above, were collected by centrifugation (10009, 10 min, 4°C). The cells were resuspended in ice-cold PBS (Sigma), pH 7.4, supplemented with 0.1% bovine serum albumin (BSA; Sigma) and 0.1% o-glucose (PBG: Sigma). Four different binding assay protocols were used, as described below.
Association experiments. The resuspended CEM cells (2.5 x 10 6 cells in 100 J-LI of PBG) were incubated at room temperature for 30 min in the presence or absence of 5 J-Lg mr " of the anti-CD4a antibody, G17-2. Prior experiments showed that 1251_gp120 binding increases linearly with cell number between 1.25 x 10 6 and 5 x 10 6 cells per incubation (data not shown). Following this preincubation, a 100 J-LI solution of 1251-gp120 (O.4nM) was added and the mixture was incubated for varying lengths of time at 37"C. The incubation was terminated by collecting the cells by centrifugation (10009, 30 seconds, 4°C). The cells were washed with fresh ice-cold PBG and repelleted twice. For quantification, the final pellet was collected by filtration using an automatic cell harvester (Tomtec, Orange, CT) onto filters presoaked in 0.1% BSA. The filters were washed twice after the filtration with ice-cold PBS supplemented with 0.1% BSA. Radioactivity trapped by the filters was measured by scintillation counting using a Betaplate counter (LKB) normalized with the appropriate standards. Non-specific binding was taken as that occurring in the incubations in which the G17-2 antibody was present.
Dissociation experiments. Following the preincubation at room , temperature and a 2-h incubation with the ligand at 37°C, the ! CEM cells were collected by centrifugation and washed, as described above. The cells were then re-incubated at 37"C for gp120 binding to the CD4a antigen 181 various periods of time in fresh PBG. In some experiments, the re-incubation was done in the presence of 5J-Lg mr' of G17-2.
The results did not differ from those in which the antibody was absent. Finally, the cells were again collected by centrifugation, washed, and the binding quantified as in the inhibition experiments. Specific binding was measured as defined in the association experiments.
Saturation experimnets. These experiments were performed using the same procedure as the association experiments except that multiple concentrations of 1251-gp120, ranging from 3.2pM to 3.2 nM, were used. After addition of the ligand the mixture was incubated for 2 h at 37"C. In one experiment the incubation was continued for 3h, and in another for 5. Use of longer incubation periods did not affect the binding results, suggesting that equilibrium had been reached by 2 h and that the ligand was stable. Non-specific binding was defined for each ligand Concentration using 5J-Lg mr ' of G17-2. The cells were collected and washed, and the binding quantified, as described for the association experiments. Since all conditions described above produced similar results, the data were combined. Additional saturation experiments were performed under special conditions. In two cases, the cells were preincubated with OKT4 (1J-Lg mr") at 4°C for 30 min, after which time a goatderived anti-mouse IgG (10 J-Lg ml-1) was added. The incubation was continued for 30 min at 23°C followed by the normal saturation binding procedure. In a third case, the saturation experiment was carried out at 4°C. The incubation period for this experiment was extended to 51f2h, the time necessary to achieve maximum binding at this temperature (data not shown). In a fourth case, U937 cells were used in place of the CEM cells. Finally, the initial portion of the saturation curve (0.02-1 nM 1251-gp120) was repeated with the same concentrations of CEM cells and ligand, but at 10 times the incubation volume. All saturation data were analysed using the Ligand1 computer program (Lundeen and Gordon, 1986) .
Inhibition experiments. These experiments were also performed in the same manner as the association experiments, except that 80 J-LI of the CEM cell suspension, containing 2.5 x 10 6 cells, were combined with 20 J-LI of a solution containing the substances to be tested, or its vehicle. The vehicle was either PBG or 25mM Tris acetate buffer (Sigma),pH 6.8, containing 0.2% ethanol and 0.2% emulphor. Neither vehicle solution had a significant effect on the binding. The 1251-gp120 (O.4nM in 100J-L1) was added and the mixture was incubated for 2 h at 37"C. The cells were collected and washed, and the binding quantified, as described above..
In each type of binding experiment, ligand prepared from both virally isolated and cell-derived gp120 was used. In the saturation experiments, recombinant gp120 was also used. No differences in results could be demonstrated based on the type of ligand employed. The data were, therefore, combined.
